Eli Lilly Will Use GeneNews' Osteoarthritis Biomarker Technology | GenomeWeb

NEW YORK (GenomeWeb News) – GeneNews said today that under a new agreement drugmaker Eli Lilly will have select access to its osteoarthritis genomic biomarker program.

Toronto-based GeneNews specializes in using functional genomics for biomarker-based early disease diagnosis.

GeneNews Lead Director and Interim CEO Heiner Dreismann said in statement that the firm's Sentinel Principle technology "can be applied to identify biomarkers for virtually any disease or condition and was extensively validated in our osteoarthritis program."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.